Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine. (MYLY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01848652
Recruitment Status : Terminated (The laboratory's partner on this study decides to terminate the contract with the CHRU Brest, because of the difficulty of the recruitment.)
First Posted : May 7, 2013
Last Update Posted : July 14, 2015
Sponsor:
Collaborator:
Teva Pharmaceuticals USA
Information provided by (Responsible Party):
University Hospital, Brest

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : May 2015
Actual Study Completion Date : May 2015